MedTrace Logo

C-Reactive Protein (CRP) in Obese Diabetic Women

NCT00262548 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-08-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosuvastatin; improvement of lipid profile

Sponsors & Collaborators

  • Mexican National Institute of Public Health

    collaborator OTHER_GOV

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Astra Zeneca Mexico Medical Director, MD · AstraZeneca

  • Simón Barquera Cervera, MD · Mexican National Institute of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262548 on ClinicalTrials.gov